178 related articles for article (PubMed ID: 36383412)
21. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.
Tomlins SA; Rhodes DR; Perner S; Dhanasekaran SM; Mehra R; Sun XW; Varambally S; Cao X; Tchinda J; Kuefer R; Lee C; Montie JE; Shah RB; Pienta KJ; Rubin MA; Chinnaiyan AM
Science; 2005 Oct; 310(5748):644-8. PubMed ID: 16254181
[TBL] [Abstract][Full Text] [Related]
22. SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer.
Rickman DS; Pflueger D; Moss B; VanDoren VE; Chen CX; de la Taille A; Kuefer R; Tewari AK; Setlur SR; Demichelis F; Rubin MA
Cancer Res; 2009 Apr; 69(7):2734-8. PubMed ID: 19293179
[TBL] [Abstract][Full Text] [Related]
23. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
Winnes M; Lissbrant E; Damber JE; Stenman G
Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
[TBL] [Abstract][Full Text] [Related]
24. Selective inhibition of prolactin gene transcription by the ETS-2 repressor factor.
Day RN; Liu J; Sundmark V; Kawecki M; Berry D; Elsholtz HP
J Biol Chem; 1998 Nov; 273(48):31909-15. PubMed ID: 9822660
[TBL] [Abstract][Full Text] [Related]
25. ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients.
Baena E; Shao Z; Linn DE; Glass K; Hamblen MJ; Fujiwara Y; Kim J; Nguyen M; Zhang X; Godinho FJ; Bronson RT; Mucci LA; Loda M; Yuan GC; Orkin SH; Li Z
Genes Dev; 2013 Mar; 27(6):683-98. PubMed ID: 23512661
[TBL] [Abstract][Full Text] [Related]
26. ETS rearrangements and prostate cancer initiation.
Carver BS; Tran J; Chen Z; Carracedo-Perez A; Alimonti A; Nardella C; Gopalan A; Scardino PT; Cordon-Cardo C; Gerald W; Pandolfi PP
Nature; 2009 Feb; 457(7231):E1; discussion E2-3. PubMed ID: 19212347
[TBL] [Abstract][Full Text] [Related]
27. Genomic structure and chromosomal localization of the novel ETS factor, PE-2 (ERF).
de Castro CM; Rabe SM; Langdon SD; Fleenor DE; Slentz-Kesler K; Ahmed MN; Qumsiyeh MB; Kaufman RE
Genomics; 1997 Jun; 42(2):227-35. PubMed ID: 9192842
[TBL] [Abstract][Full Text] [Related]
28. Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements.
Paulo P; Ribeiro FR; Santos J; Mesquita D; Almeida M; Barros-Silva JD; Itkonen H; Henrique R; Jerónimo C; Sveen A; Mills IG; Skotheim RI; Lothe RA; Teixeira MR
Neoplasia; 2012 Jul; 14(7):600-11. PubMed ID: 22904677
[TBL] [Abstract][Full Text] [Related]
29. Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.
Lunardi A; Varmeh S; Chen M; Taulli R; Guarnerio J; Ala U; Seitzer N; Ishikawa T; Carver BS; Hobbs RM; Quarantotti V; Ng C; Berger AH; Nardella C; Poliseno L; Montironi R; Castillo-Martin M; Cordon-Cardo C; Signoretti S; Pandolfi PP
Cancer Discov; 2015 May; 5(5):550-63. PubMed ID: 25653093
[TBL] [Abstract][Full Text] [Related]
30. Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness.
Foos G; Hauser CA
Oncogene; 2000 Nov; 19(48):5507-16. PubMed ID: 11114728
[TBL] [Abstract][Full Text] [Related]
31. Testing mutual exclusivity of ETS rearranged prostate cancer.
Svensson MA; LaFargue CJ; MacDonald TY; Pflueger D; Kitabayashi N; Santa-Cruz AM; Garsha KE; Sathyanarayana UG; Riley JP; Yun CS; Nagy D; Kosmeder JW; Pestano GA; Tewari AK; Demichelis F; Rubin MA
Lab Invest; 2011 Mar; 91(3):404-12. PubMed ID: 20975660
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of full-length ETV1 transcripts in clinical prostate cancer due to gene translocation.
Gasi D; van der Korput HA; Douben HC; de Klein A; de Ridder CM; van Weerden WM; Trapman J
PLoS One; 2011 Jan; 6(1):e16332. PubMed ID: 21298110
[TBL] [Abstract][Full Text] [Related]
33. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer.
Han B; Mehra R; Dhanasekaran SM; Yu J; Menon A; Lonigro RJ; Wang X; Gong Y; Wang L; Shankar S; Laxman B; Shah RB; Varambally S; Palanisamy N; Tomlins SA; Kumar-Sinha C; Chinnaiyan AM
Cancer Res; 2008 Sep; 68(18):7629-37. PubMed ID: 18794152
[TBL] [Abstract][Full Text] [Related]
34. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss.
Chen Y; Chi P; Rockowitz S; Iaquinta PJ; Shamu T; Shukla S; Gao D; Sirota I; Carver BS; Wongvipat J; Scher HI; Zheng D; Sawyers CL
Nat Med; 2013 Aug; 19(8):1023-9. PubMed ID: 23817021
[TBL] [Abstract][Full Text] [Related]
35. Capicua suppresses YAP1 to limit tumorigenesis and maintain drug sensitivity in human cancer.
Kim JW; Luck C; Wu W; Ponce RK; Lin YK; Gupta N; Okimoto RA
Cell Rep; 2022 Oct; 41(1):111443. PubMed ID: 36198276
[TBL] [Abstract][Full Text] [Related]
36. ETV transcriptional upregulation is more reliable than RNA sequencing algorithms and FISH in diagnosing round cell sarcomas with CIC gene rearrangements.
Kao YC; Sung YS; Chen CL; Zhang L; Dickson BC; Swanson D; Vaiyapuri S; Latif F; Alholle A; Huang SC; Hornick JL; Antonescu CR
Genes Chromosomes Cancer; 2017 Jun; 56(6):501-510. PubMed ID: 28233365
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic ETS Factors in Prostate Cancer.
Nicholas TR; Strittmatter BG; Hollenhorst PC
Adv Exp Med Biol; 2019; 1210():409-436. PubMed ID: 31900919
[TBL] [Abstract][Full Text] [Related]
38. Ets domain transcription factor PE1 suppresses human interstitial collagenase promoter activity by antagonizing protein-DNA interactions at a critical AP1 element.
Bidder M; Loewy AP; Latifi T; Newberry EP; Ferguson G; Willis DM; Towler DA
Biochemistry; 2000 Aug; 39(30):8917-28. PubMed ID: 10913304
[TBL] [Abstract][Full Text] [Related]
39. Capicua regulates neural stem cell proliferation and lineage specification through control of Ets factors.
Ahmad ST; Rogers AD; Chen MJ; Dixit R; Adnani L; Frankiw LS; Lawn SO; Blough MD; Alshehri M; Wu W; Marra MA; Robbins SM; Cairncross JG; Schuurmans C; Chan JA
Nat Commun; 2019 May; 10(1):2000. PubMed ID: 31043608
[TBL] [Abstract][Full Text] [Related]
40. Downregulation of CIC does not associate with overexpression of ETV1 or MAP kinase pathway activation in gastrointestinal stromal tumors.
Schoppmann SF; Ricken G; Ilhan-Mutlu A; Nirtl N; Streubel B; Preusser M; Birner P
Cancer Invest; 2014 Aug; 32(7):363-7. PubMed ID: 24897389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
